Talk:Latrepirdine

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Latrepirdine.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Russia

Another source says "it's not marketed anywhere in the world right now, and it hasn't been approved in any country," said Dr. Rachelle Doody, the study's principal investigator".161.148.141.102 (talk) 20:02, 18 July 2008 (UTC)[reply]

That's a helpful link, but it's unclear as to what, exactly, the principal investigator is referring to by the word "it". Does she mean that "Dimebon^tm is not marketed or approved for treating alzheimer's"?. Or does she mean that "Dimebolin hydrochloride is not marketed or approved in any country, not even for use as an anti-histamine." The first meaning would undoubtedly be true, the second just seems quite unlikely for a 25-year-old substance. I couldn't find a secondary source to clarify, can anyone else? Or can anyone tell us whether it's made and offered as an antihistamine in his own country, so we can at least know whether it might be possible to find such a secondary source to cite on this question? Ohiostandard (talk) 16:16, 9 September 2009 (UTC)[reply]

How it is made

Can anyone say who made it in Russia ? or what the process was ? Is it, or the manufacturing process, protected by any patents ? Rod57 (talk) 15:52, 20 December 2009 (UTC)[reply]

Poor use of See Also

The list of other AD drugs under See Also seems to belong better to Alzheimers disease unless they are structurally or mechanistically related to dimebon/latrepiridine (in which case the relevance should be noted). Rod57 (talk) 10:49, 16 April 2011 (UTC)[reply]